Objective: Evaluate the novel, validated endpoint, Hidradenitis Suppurativa Clinical Response (HiSCR) and its utility as an outcome measure.
Hidradenitis suppurativa (HS) is a chronic, recurring, debilitating inflammatory skin disease, which mainly affects the inverse areas of the body leading to scarring and disfigurement.
Hidradenitis suppurativa (HS) is an inflammatory, debilitating follicular skin disease with recurring flare-ups.
We aimed to review the most up-to-date information regarding the epidemiology, clinical presentation, diagnostic studies, pathogenesis, comorbidities and quality of life of patients with hidradenitis suppurativa.
Objective: A review of the literature was conducted to elucidate existing information on this topic to assist in clinical decision-making for dermatologists.
In this review, we discuss the roles of IL-17A, IL-17F and IL-17C in psoriasis and HS and the strategies taken to target the IL-17 pathway therapeutically.
Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin condition that typically occurs after puberty.
It is challenging to estimate a true prevalence of hidradenitis suppurativa (HS) because it is underdiagnosed and misdiagnosed.
Containing relevant Learning Zones, guidelines, trials and news.
Hidradenitis suppurativa is a recurrent, debilitating suppurative skin disease.